Last checked at 1 Oct 2009 18:29
Stock Exchange announcement
FOR release: Thursday 1 October 2009
CELSIS INTERNATIONAL PLC
("Celsis", "the Company" or "the Group")
Celsis International PLC Transfers from Treasury and Admission of Shares; Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
Celsis International plc (LSE: CEL) ("Celsis" or the "Company") today announces that, following the exercise of options pursuant to the offer made by Nastor Investments Limited, an application is expected to be made in due course to the UK Listing Authority and to the London Stock Exchange for admission to the Official List and to trading on the London Stock Exchange's main market for listed securities (together, "Admission") of 500,326 ordinary shares of 5 pence each in the capital of the Company (the "Ordinary Shares").
The new Ordinary Shares will be issued fully paid and will rank pari passu with the existing Ordinary Shares of Celsis in all respects.
In addition, on 1 October 2009 the Company transferred 590,515 Ordinary Shares held in treasury to certain optionholders in satisfaction of the exercise of options pursuant to the offer made by Nastor Investments Limited.
Voting Rights and Capital
The Company also announces that, in accordance with DTR 5.6 and Listing Rule 12.6.4, as a result of the exercise of options under the cashless Net Settlement Arrangements made available to optionholders by Nastor Investments Limited, the Company has issued 500,326 new Ordinary Shares to optionholders and transferred to optionholders out of treasury 590,515 Ordinary Shares, thereby increasing the issued ordinary share capital of Celsis to 22,983,369 Ordinary Shares. Following the transfer, Celsis does not hold any shares in treasury.
The above total voting rights figure of 22,983,369 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Service Authority's Disclosure and Transparency Rules.
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
In addition, the Company announces, in accordance with DTR 3.1.2R, that it received notification on 1 October 2009 from Jay LeCoque and Christian Madrolle that they had exercised options over 615,005 Ordinary Shares and 470,822 Ordinary Shares respectively as part of the cashless Net Settlement Arrangements made available to optionholders by Nastor Investments Limited.
Mr LeCoque and Mr Madrolle immediately accepted the offer from Nastor Investments Limited in relation to such Ordinary Shares.
Following these transactions, Mr LeCoque's and Mr Madrolle's beneficial interests in the Company are nil.
For further information contact:
| Enquiries: |
|
|
|
|
| Celsis International plc | Tel: 01223 598 428 |
| Jay LeCoque |
|
| Robyn LaLonde |
|
|
|
|
| Nomura Code Securities | Tel: 020 7776 1200 |
| Chris Collins |
|
| Phil Walker |
|
|
|
|
| Financial Dynamics | Tel: 020 7831 3113 |
| Jonathan Birt |
|
| Susan Quigley |
|
Notes to editors
Celsis International plc
Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries. Each Celsis business has the capacity to deliver substantial time and cost savings to its customers, in addition to ensuring product quality and safety for consumers. Celsis' extensive client base includes many of the world's leading pharmaceutical and consumer products companies.
Celsis Rapid Detection utilises proprietary enzyme technology to develop and supply diagnostic testing instruments and consumables for the rapid detection of microbial contamination in pharmaceutical and consumer products. These rapid testing systems provide significant economic value by reducing the time it takes to test and release raw materials, in process and finished goods to market.
Celsis Analytical Services provides cost effective outsourced analytical laboratory services to the pharmaceutical and consumer products industries. Its comprehensive service offerings include a full spectrum of laboratory services used in the ongoing manufacture of our customers' products ranging from analytical chemistry and biological sciences to stability storage and testing.
Celsis In Vitro Technologies (IVT) employs proprietary expertise in hepatocyte (liver cell) technology to supply in vitro testing products to the pharmaceutical industry. IVT's consumable testing products screen drug compounds for liver toxicity early in the drug discovery process, thereby reducing the time and cost of further development or research on those compounds that will not be properly metabolised by the human liver.
Further information can be found on its website at www.celsis.com.